Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma And Health Reform: Staying On The Sidelines Works Out

Executive Summary

The failure of the GOP effort to repeal the Affordable Care Act came after a lot of health care stakeholders warned that proposals in the Senate would lead to a disaster. The pharmaceutical industry maintained its silence on the bill – and probably ends up as one of the winners as the dust settles.

You may also be interested in...



Novartis And Cohen: A View Into Pharma's Policy Concerns As Trump Took Office

As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.

Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

White House Opioid Report Urges Better Access To Overdose Treatment; Mandatory Prescriber Education

Pricing of anti-addiction therapies could come under more pressure from HHS if Trump Administration accepts White House commission recommendation to declare public health emergency on opioid crisis.

Related Content

Topics

UsernamePublicRestriction

Register

PS121226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel